New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 0.48 mg/ml equivalent to 0.4 mg/ml salbutamol (or 2 mg salbutamol per 5 ml);   - syrup - 2 mg/5ml - active: salbutamol sulfate 0.48 mg/ml equivalent to 0.4 mg/ml salbutamol (or 2 mg salbutamol per 5 ml)   excipient: citric acid monohydrate hypromellose orange flavour 17-42-8187 purified water saccharin sodium sodium benzoate sodium chloride sodium citrate dihydrate - ventolin syrup is indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. ventolin syrup is suitable oral therapy for children or those adults who prefer liquid medicines.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage);   - solution for inhalation - 2.5mg/2.5ml - active: salbutamol sulfate 1 mg/ml (plus 0.2mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage);   - solution for inhalation - 5mg/2.5ml - active: salbutamol sulfate 2 mg/ml (plus 0.4mg/ml overage)   excipient: sodium chloride sulfuric acid water for injection - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relations

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - inhaler - salbutamol as sulfate 100 mcg/dose - salbutamol - salbutamol - ventolin inhaler cfc free is a short-acting (4 to 6 hour) bronchodilator with fast (within 5 minutes) onset in reversible airways obstruction. it is particularly suitable for the relief and prevention of asthma symptoms it should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognized by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure).ventolin inhaler cfc free is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - solution for injection - salbutamol as sulfate 0.5 mg/ml - salbutamol - salbutamol - ventolin injection is indicated in adults.ventolin injection provides short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction. it is indicated for the relief of severe bronchospasm.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - solution for nebulisation - salbutamol as sulfate 5 mg/ml - selective beta-2 adrenoreceptor agonists - ventolin respirator solution is indicated in adults, adolescents and children.ventolin respirator solution is indicated as a rescue treatment of chronic bronchospasm unresponsive to conventional therapy, and in the treatment of acute severe asthma.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects: pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relatio

United States - English - NLM (National Library of Medicine)

stat rx usa llc - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relations

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol sulfate 108 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. teratogenic effects pregnancy category c. there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relations